Susan Bal

Hematology | Oncology
2000 6th Ave S
Birmingham, AL 35233

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 70 publications

Real-world outcomes with BCMA- and GPRC5D-targeting bispecific antibodies in plasma cell leukemia.

Real-world outcomes with BCMA- and GPRC5D-targeting bispecific antibodies in plasma cell leukemia.

Journal: Blood advances
Published: April 21, 2026

Real-World Outcomes with BCMA- and GPRC5D-Targeting Bispecific Antibodies in Plasma Cell Leukemia.

Real-World Outcomes with BCMA- and GPRC5D-Targeting Bispecific Antibodies in Plasma Cell Leukemia.

Journal: Blood advances
Published: April 21, 2026

Real-World Evaluation of Talquetamab for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM): An International Myeloma Working Group Immunotherapy Registry Real-World Analysis.

Real-World Evaluation of Talquetamab for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM): An International Myeloma Working Group Immunotherapy Registry Real-World Analysis.

Journal: American journal of hematology
Published: March 04, 2026

Treatment of Multiple Myeloma: ASCO-Ontario Health (Cancer Care Ontario) Living Guideline.

Treatment of Multiple Myeloma: ASCO-Ontario Health (Cancer Care Ontario) Living Guideline.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: January 06, 2026

Early mortality with bispecific antibody therapy in RRMM: an IMWG immunotherapy database real-world analysis.

Early mortality with bispecific antibody therapy in RRMM: an IMWG immunotherapy database real-world analysis.

Journal: Blood advances
Published: December 01, 2025

Early Mortality with Bispecific Antibody Therapy in RRMM: An IMWG Immunotherapy Database Real-World Analysis.

Early Mortality with Bispecific Antibody Therapy in RRMM: An IMWG Immunotherapy Database Real-World Analysis.

Journal: Blood advances
Published: December 01, 2025

Redefining functional high-risk multiple myeloma in the context of upfront quadruplet therapy and autologous stem cell transplantation.

Redefining functional high-risk multiple myeloma in the context of upfront quadruplet therapy and autologous stem cell transplantation.

Journal: Cancer
Published: November 22, 2025

Validation of the 2025 IMS/IMWG risk classification in patients with newly diagnosed multiple myeloma treated with quadruplets and autologous stem cell transplant.

Validation of the 2025 IMS/IMWG risk classification in patients with newly diagnosed multiple myeloma treated with quadruplets and autologous stem cell transplant.

Journal: British journal of haematology
Published: November 14, 2025

Distinct trajectory of measurable residual disease in t(11;14) myeloma treated with quadruplet therapy.

Distinct trajectory of measurable residual disease in t(11;14) myeloma treated with quadruplet therapy.

Journal: Blood
Published: October 07, 2025

Distinct trajectory of measurable residual disease in t(11;14) myeloma treated with quadruplet therapy.

Distinct trajectory of measurable residual disease in t(11;14) myeloma treated with quadruplet therapy.

Journal: Blood
Published: October 07, 2025

Arlocabtagene autoleucel-a GPRC5D-targeted CAR T-cell therapy in heavily pretreated relapsed/refractory multiple myeloma.

Arlocabtagene autoleucel-a GPRC5D-targeted CAR T-cell therapy in heavily pretreated relapsed/refractory multiple myeloma.

Journal: Blood
Published: July 24, 2025

Arlocabtagene autoleucel: a GPRC5D-targeted CAR T-cell therapy for heavily pretreated relapsed/refractory multiple myeloma.

Arlocabtagene autoleucel: a GPRC5D-targeted CAR T-cell therapy for heavily pretreated relapsed/refractory multiple myeloma.

Journal: Blood
Published: July 24, 2025
Showing 1-12 of 70

Last Updated: 09/26/2026